These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20377768)

  • 1. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients.
    Jing S; Kezhou Y; Hong Z; Qun W; Rong W
    Nephrology (Carlton); 2010 Feb; 15(1):27-32. PubMed ID: 20377768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
    Fang W; Oreopoulos DG; Bargman JM
    Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients.
    Kolesnyk I; Noordzij M; Dekker FW; Boeschoten EW; Krediet RT
    Nephrol Dial Transplant; 2009 Jan; 24(1):272-7. PubMed ID: 18676349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients.
    Kolesnyk I; Dekker FW; Noordzij M; le Cessie S; Struijk DG; Krediet RT
    Perit Dial Int; 2007; 27(4):446-53. PubMed ID: 17602154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
    Trošt Rupnik A; Pajek J; Guček A; Osredkar J; Kovač D; Bren A; Klančič D; Saksida S; Rus I; Globokar M; Drozg A; Lešnik M; Plešivčnik Z; Ekart R; Lopert S; Lindič J
    Ther Apher Dial; 2013 Aug; 17(4):425-30. PubMed ID: 23931884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
    Garthwaite E; Bhandari S
    Artif Organs; 2009 Aug; 33(8):641-7. PubMed ID: 19624582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.
    Kolesnyk I; Struijk DG; Dekker FW; Krediet RT
    Neth J Med; 2010 Jan; 68(1):15-23. PubMed ID: 20103817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study.
    Reyes-Marín FA; Calzada C; Ballesteros A; Amato D
    Rev Invest Clin; 2012; 64(4):315-21. PubMed ID: 23227581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on RAAS blockade and peritoneal membrane preservation: the ace of art.
    Wontanatawatot W; Eiam-Ong S; Leelahavanichkul A; Kanjanabuch T
    J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S175-83. PubMed ID: 22043587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of peritoneal transport properties at onset of peritoneal dialysis and longitudinal follow-up.
    Clerbaux G; Francart J; Wallemacq P; Robert A; Goffin E
    Nephrol Dial Transplant; 2006 Apr; 21(4):1032-9. PubMed ID: 16364990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P
    Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.